bemarituzumab (AMG 552) / Amgen 
Welcome,         Profile    Billing    Logout  
 0 Diseases   6 Trials   6 Trials   251 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bemarituzumab (AMG 552) / Amgen
FORTITUDE-101, NCT05052801 / 2021-003461-35: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting
3
547
Europe, Canada, Japan, US, RoW
Bemarituzumab, mFOLFOX6, Placebo
Amgen, Zai Lab (China only)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
FORTITUDE-102, NCT05111626 / 2021-003477-61: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Active, not recruiting
3
507
Europe, Canada, Japan, US, RoW
Bemarituzumab, AMG 552, Nivolumab, Chemotherapy, Placebo
Amgen, Amgen Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
09/26
09/26
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Not yet recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
FORTITUDE-301, NCT05325866 / 2021-006386-38: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Recruiting
1/2
303
Europe, Canada, Japan, US, RoW
Bemarituzumab, AMG 552
Amgen, Amgen Inc.
Solid Tumors
03/26
12/27
FORTITUDE-103, NCT05322577: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Recruiting
1/2
80
Japan, US, RoW
Bemarituzumab, CAPOX, SOX, Nivolumab
Amgen
Gastric Cancer, Gastroesophageal Junction Cancer
03/26
04/28
NCT05913115: A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Completed
1
6
Japan
FPA144, Bemarituzumab
Amgen
Gastric or Gastroesophageal Cancer
06/18
06/18
FORTITUDE-201, NCT05267470: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression

Terminated
1
74
Europe, Japan, US, RoW
Bemarituzumab, AMG 552, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
Amgen
Squamous-Cell Non-Small-Cell Lung Cancer
04/24
05/24
NCT03801278: An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

No Longer Available
N/A
NA
FPA144, Bemarituzumab
Five Prime Therapeutics, Inc.
Recurrent Bladder Cancer
 
 

Download Options